Miles Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History

Miles Capital’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-1,678	Closed	-$261K	–	205
2017 Q2	$261K	Hold	1,678	–	–	0.14%	132
2017 Q1	$244K	Buy	+1,678	New	+$219K	0.14%	142
2013 Q4	–	Sell	-3,534	Closed	-$325K	–	112
2013 Q3	$325K	Sell	3,534 -899	-20%	-$72.5K	0.19%	93
2013 Q2	$305K	Buy	+4,433	New	+$271K	0.14%	108

Other funds holding JAZZ

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

SIG

Senator Investment Group New York $2.74B AUM 55.95% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Miles Capital's JAZZ Position: Q3 2017 in Review

Miles Capital sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2017, closing a stake of 1,678 shares — an estimated $261K sold.

Miles Capital first reported a position in JAZZ in Q2 2013 and held it in 4 quarters. The position peaked at $325K in Q3 2013. 303 funds tracked by Wall St. Rank hold JAZZ as of Q3 2017.

Miles Capital reported no remaining Jazz Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
Miles Capital sold 1,678 Jazz Pharmaceuticals shares in Q3 2017, an estimated $261K.
Miles Capital first reported a position in Jazz Pharmaceuticals in Q2 2013 and held it in 4 quarters.
Miles Capital's Jazz Pharmaceuticals position peaked at $325K in Q3 2013.
303 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2017.

Based on Miles Capital's 13F filing for Q3 2017, filed 13 Nov 2017.